Research programme: botulinum toxins - Ipsen BioinnovationAlternative Names: botulinum neurotoxins; SXN
Latest Information Update: 15 Dec 2016
At a glance
- Originator Syntaxin
- Developer Ipsen Bioinnovation
- Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Recombinant proteins
- Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified